Table 2. Characteristics of subcohort B.

	COVID-19-positive ESKD patients (n = 46)	COVID-19-negative ESKD controls (n = 11)*
Age Median (IQR)	64.3 60.3–73.0	71.6 (61.7–73.9)
Sex M F	32 (69.6%) 14 (30.4%)	8 (72.3%) 3 (27.3%)
Ethnicity White Black South Asian Asian (other) Other	11 (23.9%) 8 (17.4%) 12 (26.1%) 7 (15.2%) 8 (17.4%)	3 (27.3%) 3 (27.3%) 3 (27.3%) 0 2 (18.2%)
Diabetes	29 (63.0%)	6 (54.5%)
Current smoker	2 (4.3%)	0 (%)
ESKD cause DN Genetic GN HTN/vascular Other Unknown	19 (41.3%) 1 (2.2%) 7 (15.2%) 3 (6.5%) 3 (6.5%) 13 (28.3%)	5 (45.5%) 0 1 (9.1%) 1 (9.1%) 2 (18.2%) 2 (18.2%)
Hospitalisation due to COVID-19	41 (89.1%)	N/A
Severe or critical COVID-19	33 (71.7%)	N/A
Fatal COVID-19	9 (19.6%)	N/A

DN = diabetic nephropathy. GN = glomerulonephritis. HTN = hypertension. IQR = inter-quartile range. ‘South Asian’ represents individuals with Indian, Pakistani, or Bangladeshi ancestry. Subsets defined according to peak WHO severity over the course of the illness. N/A = not applicable. *These 11 controls are a subset of the control patients used in subcohort A.